.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD14_VonoprazanAmoxicillinAnd.VonoprazanAmoxicillinAnd .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD14_VonoprazanAmoxicillinAnd.VonoprazanAmoxicillinAnd| name: | VonoprazanAmoxicillinAndClarithromycin | |
| ATC code: | A02BD14 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 200 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
A combination therapy of vonoprazan (a potassium-competitive acid blocker), amoxicillin (a broad-spectrum penicillin antibiotic), and clarithromycin (a macrolide antibiotic) mostly used for eradication of Helicobacter pylori infection. This triple therapy is an alternative to standard proton pump inhibitor-based regimens and is approved and used in several countries as a first-line treatment for H. pylori.
Typical pharmacokinetic parameters in healthy adult volunteers after oral administration of the triple therapy; values are averaged or estimated based on reported literature for individual components and pharmacokinetic properties when used in combination.
Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775